Rita Oladele

Dr. Rita Oladele


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2017 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Felix BognominFelix Bognomin
Felix Bognomin
SGSara Gago
Sara Gago
RORita Oladele
Rita Oladele
DDDavid W. Denning
David W. Denning
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.

1 June 2021 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
PKPhilipp Koehler
Philipp Koehler
MBMatteo Bassetti
Matteo Bassetti
ACArunaloke Chakrabarti
Arunaloke Chakrabarti
SCSharon Chen
Sharon Chen
Arnaldo L. ColomboArnaldo L. Colombo
Arnaldo L. Colombo
OCOliver A. Cornely
Oliver A. Cornely

18 January 2018 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
RORita Oladele
Rita Oladele
OAOlusola O. Ayanlowo
Olusola O. Ayanlowo
MRMalcolm D. Richardson
Malcolm D. Richardson
DDDavid W. Denning
David W. Denning
Histoplasmosis in Africa has markedly increased since the advent of the HIV/AIDS epidemic but is under-recognised. Pulmonary histoplasmosis may be misdiagnosed as tuberculosis (TB). In the last six decades (1952–2017), 470 cases of histoplasmosis have been reported. HIV-infected patients accounted for 38% (178) of the cases. West Africa had the highest number of recorded cases with 179; the majority (162 cases) were caused by Histoplasma capsulatum var. dubuosii (Hcd). From the Southern African region, 150 cases have been reported, and the majority (119) were caused by H. capsulatum var. capsulatum (Hcc). There have been 12 histoplasmin skin test surveys with rates of 0% to 35% positivity. Most cases of Hcd presented as localised lesions in immunocompetent persons; however, it was disseminated in AIDS patients. Rapid diagnosis of histoplasmosis in Africa is only currently possible using microscopy; antigen testing and PCR are not available in most of Africa. Treatment requires amphotericin B and itraconazole, both of which are not licensed or available in several parts of Africa.

14 February 2018 in Mycoses
Verified
Journal Article
Closed access
PDF file
Felix BognominFelix Bognomin
Felix Bognomin
RORita Oladele
Rita Oladele
SGSara Gago
Sara Gago
CMCaroline B. Moore
Caroline B. Moore
MRMalcolm D. Richardson
Malcolm D. Richardson

27 June 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
SPSarika Parambath
Sarika Parambath
Aiken DaoAiken Dao
Aiken Dao
HKHannah Yejin Kim
Hannah Yejin Kim
SZShukry Zawahir
Shukry Zawahir
Ana Alastruey-IzquierdoAna Alastruey-Izquierdo
Ana Alastruey-Izquierdo
JBJustin Beardsley
Justin Beardsley
Candida albicans is a common fungal pathogen and amongst the leading causes of invasive candidiasis globally. This systematic review examines the characteristics and global impact of invasive infections caused by C. albicans. We searched on PubMed and Web of Science for studies reporting on criteria such as mortality, morbidity, drug resistance, preventability, yearly incidence, and distribution/emergence during the period from 2016 to 2021. Our findings indicate that C. albicans is the most common Candida species causing invasive disease and that standard infection control measures are the primary means of prevention. However, we found high rates of mortality associated with infections caused by C. albicans. Furthermore, there is a lack of data on complications and sequelae. Resistance to commonly used antifungals remains rare. Although, whilst generally susceptible to azoles, we found some evidence of increasing resistance, particularly in middle-income settings—notably, data from low-income settings were limited. Candida albicans remains susceptible to echinocandins, amphotericin B, and flucytosine. We observed evidence of a decreasing proportion of infections caused by C. albicans relative to other Candida species, although detailed epidemiological studies are needed to confirm this trend. More robust data on attributable mortality, complications, and sequelae are needed to understand the full extent of the impact of invasive C. albicans infections.

28 April 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
BEBASSEY EKENG
BASSEY EKENG
ADAdeyinka Afolake Davies
Adeyinka Afolake Davies
IOIriagbonse Iyabo Osaigbovo
Iriagbonse Iyabo Osaigbovo
AWAdilia Warris
Adilia Warris
RORita Oladele
Rita Oladele
DDDavid W. Denning
David W. Denning
Fungal infections commonly present with myriad symptoms that mimic other clinical entities, notable amongst which is tuberculosis. Besides histoplasmosis and chronic pulmonary aspergillosis, which can mimic TB, this review has identified several other fungal infections which also do. A total of 80 individual cases misdiagnosed as TB are highlighted: aspergillosis (n = 18, 22.5%), histoplasmosis (n = 16, 20%), blastomycosis (n = 14, 17.5%), cryptococcosis (n = 11, 13.8%), talaromycosis (n = 7, 8.8%), coccidioidomycosis (n = 5, 6.3%), mucormycosis (n = 4, 5%), sporotrichosis (n = 3, 3.8%), phaeohyphomycosis (n = 1, 1.3%) and chromoblastomycosis (n = 1, 1.3%). Case series from India and Pakistan reported over 100 cases of chronic and allergic bronchopulmonary aspergillosis had received anti-TB therapy before the correct diagnosis was made. Forty-five cases (56.3%) had favorable outcomes, and 25 (33.8%) died, outcome was unclear in the remainder. Seventeen (21.3%) cases were infected with human immunodeficiency virus (HIV). Diagnostic modalities were histopathology (n = 46, 57.5%), culture (n = 42, 52.5%), serology (n = 18, 22.5%), cytology (n = 2, 2.5%), gene sequencing (n = 5, 6.3%) and microscopy (n = 10, 12.5%) including Gram stain, India ink preparation, bone marrow smear and KOH mount. We conclude that the above fungal infections should always be considered or ruled out whenever a patient presents with symptoms suggestive of tuberculosis which is unconfirmed thereby reducing prolonged hospital stay and mortalities associated with a delayed or incorrect diagnosis of fungal infections.